Encouraging long‐term outcomes reported in patients with stage I non‐small cell lung cancer treated with stereotactic ablative radiotherapy | Zendy

Barton Mary Kay | Zendy

Open Access

Encouraging long‐term outcomes reported in patients with stage I non‐small cell lung cancer treated with stereotactic ablative radiotherapy

Author(s) -

Barton Mary Kay

Publication year - 2017

Publication title -

ca: a cancer journal for clinicians

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 62.937

H-Index - 168

eISSN - 1542-4863

pISSN - 0007-9235

DOI - 10.3322/caac.21375

Subject(s) - sabr volatility model , ablative case , medicine , stage (stratigraphy) , radiation therapy , lung cancer , radiosurgery , population , oncology , surgery , volatility (finance) , paleontology , stochastic volatility , environmental health , financial economics , economics , biology

Key Points At a median of 7.2 years of follow‐up, patients with stage I NSCLC who were treated with SABR had outcomes comparable to those noted among patients with stage I disease who were treated with surgery. Research is needed to define whether SABR can be applied to a wider population of patients with NSCLC and how to optimally combine it with systemic therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research